Aristotle University Of Thessaloniki (AUTH)
Διερεύνηση της νευροπροστατευτικής δράσης της τοπιραμάτης σε τραυματικό πρότυπο εγκεφαλικής βλάβης σε επίμυες
Abstract
dc:descriptionTrauma is today the leading cause of death in ages under 45 years in Western societies while in approximately half of these deaths coexist severe head injuries as mainly responsible for the death of the patient. The prognosis of head injuries despite improvements in recent years is still heavy with high social and economic costs. Traumatic brain injuries are distinguished between primary injuries which lead to a definitive and irreversible loss of neural tissue and the only way of dealing with is prevention, and secondary which appear later and allow possibilities for intervention. The modern therapeutic approach aims to restrict as far as possible the secondary damage addressing the causes that lead to it. The treatment of the systematic causes of secondary damage led to a significant improvement in the prognosis of head injuries over the last decades but this improvement stagnated over the recent years. Considering these facts the research is directed towards a better understanding of the pathophysiology of the head injury with a view to discover drugs and substances that could protect the traumatised brain tissue from secondary damages m a biochemical level. A large number of substances has been evaluated over the recent years for their neuroprotective properties in various experimental models of stroke, epileptic activity or injury. Central position in these investigations hold the antiepileptic drugs this diverse group of chemical substances whose mechanisms of action are closely related to the mechanisms of cell death, a fact that led to the assumption that antiepileptics might have a neuroprotective effect apart from their antiepileptic action. Topiramate, a new generation antiepileptic drug with multiple mechanisms of action and particularly favorable pharmacokinetic profile appears to have many prospects in this direction. Preclinical studies in models of brain ischemia and epilepsy proved its neuroprotective activity. The only study that evaluated topiramate in a model of traumatic brain injury presented moderate and equivocal results. The purpose of this study is to investigate the neuroprotective effects of topiramate in a rat model of traumatic brain injury. For the purposes of the study a new model of traumatic brain injury was constructed, characterized by credibility repeatability accuracy and low cost. Seventy-five male Wistar rats aging about three months and weighting 340-470 gr were used twelve of which were used for the standardization of the model. There were two studies: (a) the first examined the action of topiramate administered intraperitoneally in dosages of 40 and 60 mg/kg when compared with a control group that received placebo in clinical and histopathological level and (b) the second examined the action of topiramate administered intraperitoneally in a dosage of 60 mg/kg on the extent of brain edema formation. The results can be summarized as follows: (a) topiramate administered in doses of 40 and 60 mg/kg improves the neurological performance of the rats already from the first 10 days after the injury and leads to faster recovery without the higher dosage achieving better results, (b) topiramate administered in the aforementioned doses does not reduce the dimensions of the final anatomic lesion, (c) topiramate administered in a dosage of 60mg/kg does not attenuate statistically significantly the degree of brain edema although the animals which received the drug tended to show lower levels of edema formation in relation to those which did not and (d) the new model of traumatic brain injury in the rat with the weight drop technique set up for the needs of the study is simple, reliable repeatable with sufficient accuracy and has a low cost. In conclusion topiramate has been proved to possess neuroprotective properties even in a model of traumatic brain injury in a clinical level without presenting any influence in the degree of the final anatomic damage. Evidence has been also found that topiramate might reduce the degree of brain edema. This study confirms the findings of previous studies raises more vigorously matters relating to the beneficial impact of topiramate in brain edema and furthermore demonstrates that doses exceeding 40mg/kg do not give better results but probably slightly worse than smaller doses. Topiramate is a time honoured reliable medicinal product already used in clinical practice. This study might help towards opening the way for the introduction of topiramate in clinical studies which might demonstrate its beneficial action in humans and could make it a likely neuroprotective medicinal product of the futurefor traumatic brain injury.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kouzounias, Konstantinos
- Κουζούνιας, Κωνσταντίνος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23145